Wings for Crossover Helps School Establish Food Security

The founder of Integrated Oncology Network, LLC, Jeffrey A. Goffman leads the radiation oncology management and cancer center development company as its chairman and CEO. He also founded OnCURE Medical Corp., one of the nation’s premier providers of radiation oncology therapy, and U.S. Diagnostic, Inc., a consolidator of outpatient diagnostic imaging facilities. Outside the office, Jeffrey Goffman enjoys several leisure and recreational activities and supports numerous charitable endeavors, especially the American Cancer Society and Wings for Crossover.

Wings for Crossover, a 501(c)3 organization founded in 2013 by Jim Conti and Chad Cooper, supports the activities of the Crossover International Academy, which serves a student population of about 250 children in the area around Ghana’s Lake Volta. The Academy serves not only as a school for the children, who are either orphans or former slaves, but also provides them with food and shelter.

Although Wings for Crossover tried to focus its efforts on building a new school to replace the ramshackle structures the Academy was using, it quickly became clear that providing a secure, reliable food supply for the students was equally pressing. The organization thus invested in an aquaponic farming system for the school. This combines fish farming, or aquaculture, with hydroponics, the farming of plants without soil, in a symbiotic system.

Operated primarily by students, the Academy’s aquaponics system can support 4,000 tilapia and 3,000 plants. It uses 27,000 gallons of water, which are recycled regularly between the fish ponds and the plant beds, providing nutrient-rich water for the plants and returning clean, oxygen-rich water to the fish. The farm’s first fruits were harvested in March 2014, when mature fish were harvested and salted, and the first crop of tomatoes, beans, and peppers was taken to market and exchanged for bulk rice.

More information about Wings for Crossover is available at http://www.wingsforcrossover.org.

CureDuchenne’s 2015 Blingo Event

Longtime entrepreneur and healthcare professional Jeffrey Goffman serves as chief executive officer and chairman of Integrated Oncology Network, LLC. Dedicated to a number of charitable initiatives, Jeffrey Goffman is chairman of the board for CureDuchenne, a nonprofit dedicated to helping find a cure for Duchenne muscular dystrophy.

CureDuchenne has held a “Blingo to Cure Duchenne” night for the last two years to raise money for medical research. On April 11, 2015, CureDuchenne hosted its Blingo night at the Rittenhouse Hotel in Philadelphia, Pennsylvania. Among the many local companies and organizations sponsoring the fundraiser were Sugar House Casino, Spalding Automotive, and The Children’s Hospital of Philadelphia.

Hundreds of Philadelphia’s most active leaders and businesspeople attended the affair, which featured dinner and cocktails, bingo, and a live auction with elegant prizes. CBS Philly’s medical reporter Stephanie Stahl served as master of ceremonies, while a number of local celebrities, including Eagles veteran A. J. Feeley and Marisa Magnatta of Philadelphia’s Preston and Steve Show, took turns calling bingo. With the help of sponsors and participants, this year’s Blingo evening raised over $180,000 for CureDuchenne.

Duchenne Muscular Dystrophy – Severe Muscle Degeneration Disease

Integrated Oncology Network CEO and cofounder Jeffrey Goffman serves as the board chair of CureDuchenne, a nonprofit organization with headquarters in Newport Beach, California. Jeffrey Goffman and his fellow board members help lead the organization in offering support to individuals with Duchenne muscular dystrophy (DMD) and spearheading research efforts for a cure. A devastating muscle disease, DMD affects nearly 20,000 young boys across the United States and over 300,000 worldwide.

DMD is the most common and severe genetic disorder within the muscular dystrophy family. Defects in the genes responsible for producing a vital muscle protein cause the disease, and affected children usually receive the diagnosis before age 5. By the age of 12, patients lose enough leg muscle to become wheelchair bound, and most do not live past their mid-20s. Although it primarily affects boys, a small number of girls may also receive the diagnosis.

Defective genes prevent the body from forming the dystrophin protein, which leads to the progressive degeneration of muscles in nearly every part of the body and eventually compromises heart and lung health. Additional health complications include brittle bones, predisposal to pneumonia and heart failure, and the possible decline of cognitive functions. Patients can also develop fibrosis in the connective tissue between shortened muscle fibers.

CureDuchenne’s research strategies focus on providing support for new treatments to reduce DMD’s severity, drug repositioning, and protein replacement therapies. Since its establishment, the organization has advanced seven projects into human clinical trials and leveraged over $100 million from pharmaceutical companies and government agencies to fund cure research.

For additional information about DMD and the CureDuchenne organization, visit http://www.cureduchenne.org.